[IPO Status] Neosapience Subscription Day 1 Closes... 10.58 Shares Allocated in Equal Distribution, Proportional Competition Ratio at 25.26 to 1
The first day of the IPO subscription for Neosapience closed at 4 p.m. on the 10th. A total of 23,630 applications poured in on the first day alone for this subscription, conducted through Daishin Securities. As a result, the number of shares allocated in equal distribution stood at 10.58 shares ba
![[IPO Status] Neosapience Subscription Day 1 Closes... 10.58 Shares Allocated in Equal Distribution, Proportional Competition Ratio at 25.26 to 1](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F08%2F594141%2Fed32f882b01507d5%2Foriginal.webp&w=1920&q=75)
The first day of the IPO subscription for Neosapience closed at 4 p.m. on the 10th.
A total of 23,630 applications poured in on the first day alone for this subscription, conducted through Daishin Securities. As a result, the number of shares allocated in equal distribution stood at 10.58 shares based on the minimum subscription criterion, while the proportional competition ratio was tallied at 25.26 to 1.
The subscription runs until the 11th. Along with the subscription trend during the remaining schedule, the stock's direction after its listing on September 21 is also cited as a key point of interest.
According to the regulatory filing, Neosapience develops and operates 'Typecast,' a voice generation service based on its independently developed generative AI foundation model and TTS (Text-to-Speech) technology.
[This article is for reference purposes only in making investment decisions, and responsibility for investments lies with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] SK Biopharmaceuticals' Epilepsy Drug Candidate Opakalim (BHV-7000) Placed Under 'Partial Clinical Hold' in U.S. Phase 2/3 Trial…Dosing Continues for Enrolled Patients](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F07%2F587624%2F92a22c34058cf1b1%2Fvariants%2Fhero.webp&w=1920&q=75)


